Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
Not CRISPR data: the image illustrates antibody quality for visualizing CRISPR experiment results.
IGF2BP3 Double Nickase Plasmid (h): sc-402603-NIC
- Target species: human
- 20 µg of transfection-ready, purified plasmid DNA; Suitable for up to 20 transfections
- IGF2BP3 Double Nickase Plasmid (h) consists of a pair of plasmids each encoding a D10A mutated Cas9 nuclease and a target-specific 20 nt guide RNA (gRNA) designed to knockout gene expression with greater specificity than its CRISPR/Cas9 KO counterpart
- Paired gRNA sequences are offset by approximately 20 bp to allow for specific Cas9-mediated double nicking of the genomic DNA, which mimics a DSB
- One plasmid in the pair contains a puromycin-resistance gene for selection; the other plasmid in the pair contains a GFP marker to visually confirm transfection
- IGF2BP3 Double Nickase Plasmid (h) and IGF2BP3 Double Nickase Plasmid (h2) encode distinct paired gRNA designs targeting IGF2BP3. One or both designs may be available
- Following transfection, gene knockout efficiency can be assayed by WB, IF or IHC using antibody: IGF2BP3 Antibody (E-2): sc-365640
Ordering Information
| Product Name | Catalog # | UNIT | Price | Qty | FAVORITES | |
IGF2BP3 Double Nickase Plasmid (h) | sc-402603-NIC | 20 µg | $410.00 | |||
IGF2BP3 Double Nickase Plasmid (h2) | sc-402603-NIC-2 | 20 µg | $410.00 |
IGF2BP3 (IMP3) is a conserved RNA-binding protein that recognizes m6A-modified transcripts and regulates mRNA localization, stability, and translation during development and cell-state transitions. It modulates post-transcriptional gene control programs linked to proliferation, migration, and stress responses, influencing pathways such as PI3K–AKT and MAPK through stabilization of growth- and survival-associated mRNAs. IGF2BP3 is frequently re-expressed in malignant contexts and is used as a marker of aggressive tumor biology, where it can support epithelial–mesenchymal transition and altered metabolic wiring. These properties make IGF2BP3 a common target for studying oncogenic RNA regulons, m6A reader mechanisms, and context-dependent control of gene expression.
IGF2BP3 Double Nickase Plasmid (h) consists of a matched pair of plasmids engineered for high-specificity editing of the IGF2BP3 locus in human cell lines. Each plasmid expresses a Cas9 D10A nickase and a distinct sgRNA targeting opposite DNA strands within IGF2BP3. When directed to adjacent sites on opposite DNA strands, the two nickases generate offset single-strand nicks that together produce a staggered double-strand break, requiring coordinated on-target activity from both guides. The resulting DNA break is resolved by endogenous cellular repair pathways, most commonly through non-homologous end joining (NHEJ), leading to insertions or deletions that disrupt IGF2BP3 function. By requiring dual sgRNA engagement at the target locus, the double nicking approach enhances editing specificity and provides a complementary CRISPR strategy for applications where additional control over targeting precision is desired.
To support efficient identification of edited cells, one plasmid encodes GFP for fluorescent visualization of transfected populations, while the companion plasmid carries a puromycin resistance gene for antibiotic selection. Together, these features support efficient enrichment of co-transfected populations and simplify the validation of IGF2BP3-disrupted clones.
For Research Use Only. Not Intended for Diagnostic or Therapeutic Use.